Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Esophageal Neoplasms
  • Stomach Neoplasms

abstract

  • mDCF with bevacizumab appears tolerable and has notable patient outcomes in patients with advanced gastroesophageal adenocarcinoma. Six-month PFS was 79%, surpassing our predefined efficacy end point, and median and 2-year OS were 16.8 months and 37%, respectively.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3646322

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.0770

PubMed ID

  • 21189380

Additional Document Info

start page

  • 868

end page

  • 74

volume

  • 29

number

  • 7